Peptide Database

Peptide NameInebilizumab

Function Ontology

Immunology ▸ Immune modulation ▸ Immunomodulatory activity

Standard StatusStandard

Sequence Length451 amino acids

Chemical FormulaC2205H3414N588O676S16

DescriptionStandard

        EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNWVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTVRDFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    

Molecular Weight49489.27 Da

Isoelectric Point (pI)8.50

Net Charge (pH 7.0)5.54

Net Charge (pH 7.4) 4.63

Charge Density (pH 7.0) 0.0123

GRAVY Index-0.41

Hydrophobic Moment 0.62

Boman Index0.01

Instability Index44.31

Aliphatic Index 69.25

Aromaticity 0.0953

Extinction Coeff. Reduced 76320.00

Extinction Coeff. Oxidized 76945.00

The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.

Amino Acid Composition

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.

2D CHEMICAL STRUCTURE

Drag to move

Drag to move. Use the buttons to zoom.

RECORD: Rec_0188872 VERIFIED: NO

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyMonoclonal antibody

Tax ID32630

Structure & Mods

Configlinear peptide/protein therapeutic [Linear]

Chiralitycanonical L-amino-acid peptide [L]

Bio-Activity Profile

Function

Immunomodulatory

Half-LifeInebilizumab exhibits biphasic pharmacokinetics with a mean terminal half-life of 18 days.[L14315] The terminal half-life reported in phase I studies varied by dose but was typically close to 18 days, with a range of 6.8 to 18.7 days.[A214298, A214301]